All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How does BiTE® AMG 701 compare to other immunotherapies for heavily pretreated patients?
Bookmark this article
Video series
ASH 2020 | Novel therapies for RRMM
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Suzanne Lentzsch, Columbia University, New York, US. We asked, How does the bispecific T-cell engager (BiTE®) AMG 701 compare to other immunotherapies for heavily pretreated patients?
In this video, Lentzsch discusses the first-in-human clinical trial assessing AMG 701, an anti-B-cell maturation antigen BiTE® molecule, in a heavily pretreated relapsed/refractory patient population. She then compares AMG 701 with other immunotherapies and comments that it is too early to give a final verdict on the best antibody.
Video series
ASH 2020 | Novel therapies for RRMM
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox